RE:RE:PRICE PER SHAREI don't think the question is whether canopy is best in class RIGHT NOW. The question is can it / will it be the best in class in 3 years. Biotech, right now there is too much uncertainty. The questions on regulations will be very important for the future of all these mj companies. Canopy is great at marketing but how marketing will be regulated is unknown. Tabacco and pharmaceutical are great at distribution, but how distribution will look like is unknown. Basicly no one knows what the legalized recreation market landscape will be in 2 years... forget 5. At this moment it's either pick your top 3 and and hope you have a winner in them. Or make the quick buck and once the landscape is clearer you lock in you capital. You might miss some gains but it's the best way to mitigate the risk, lower opportunity cost and protect against the market volatility.